Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07015593
Starting soon Observational

Patient Journey in Advanced Gynecologic Cancers

NCT07015593 · tracked via the Priya Life Science China tracker
Sponsor
Tongji Hospital
Phase
Observational
Started
2025-07-01
Last updated
2025-06-11

Condition(s) studied

Genital Neoplasms, FemaleUterine Cervical NeoplasmsEndometrial Carcinoma

Investigational drug(s) / intervention(s)

interview

interview: 30 for Qualitative interview and 750 for quantitative survey

Study summary

This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 or older * Newly diagnosed stage III or IV CC or EC * Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis. * Told by their physician that their disease is stable. * Patients must have informed consent form (ICF) signed for the study. Exclusion Criteria: * Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. * Previously participated in or participating in a clinical trial. * Patients who received another line of therapy after initial therapy. * Unable or unwilling to provide informed consent. * Not fluent in local language. * Indicates or exhibits hearing difficulties, which would make a conversation challenging.

Primary outcome measure(s)

  • Treatment decision making — 1 day. At the time of the interview.
    1. Information seeking in treatment decision 2. Treatment decision making factors 3. Clinical trial awareness
  • Initial treatment experiences — 1 day. At the time of the interview.
    1. Influence of treatment on daily life and work 2. Information and education during treatment 3. Coordination of care 4. Overall impression on care received and doctor/nurses' availability
  • Unmet needs and gaps from diagnosis to post-treatment surveillance — 1 day. At the time of the interview.
    1. Psychological and emotional needs 2. Social support needs 3. Healthcare needs 4. Gaps during follow-up care

Trial sites (4)

FacilityCityRegionStatus
Ying Zhou Hefei Anhui
Shuzhong Yao Guangzhou Guangdong
Gang Chen Wuhan Hubei
Dongling Zou Chongqing China

More Tongji Hospital trials in China

Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease Recruiting
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease Recruiting
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders Recruiting
A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B Recruiting
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies Recruiting

Other trials for the same condition

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix Active, not recruiting
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. Starting soon
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma Recruiting
Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer Recruiting
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07015593 on ClinicalTrials.gov ↗ ← All trials in China